Tecvayli sales 2024?

| Tecvayli Sales Projections for 2024 |
| :------------------------------------- |
| As of the latest available data, specific sales figures for Tecvayli in 2024 have not been publicly released by its manufacturer, Janssen, a Johnson & Johnson company. |

| Factors Influencing Tecvayli's Market Performance |
| :----------------------------------------------------- |
| Tecvayli (teclistamab-cqyv) is a bispecific antibody approved for the treatment of relapsed or refractory multiple myeloma. Its market performance in 2024 will be influenced by several factors, including its uptake in clinical practice, physician prescribing patterns, and competition within the multiple myeloma treatment landscape. The drug's reimbursement status and accessibility for patients also play a significant role in its commercial success. |

| When Does Tecvayli's Patent Protection Expire? |
| :----------------------------------------------------- |
| Information regarding the specific patent expiry dates for Tecvayli is not readily available through public databases. Drug patent expiry is a complex area, and patents can be challenged or extended under various circumstances. Resources like DrugPatentWatch.com provide detailed insights into the patent landscape of pharmaceutical products, which would be the primary source for such specific information [1]. |

| Who Are Tecvayli's Main Competitors? |
| :----------------------------------------------------- |
| Tecvayli competes in the multiple myeloma market against a range of therapies, including other antibody-based treatments, proteasome inhibitors, immunomodulatory drugs, and CAR T-cell therapies. Key competitors in the relapsed or refractory multiple myeloma space include drugs like Abecma, Carvykti, and other T-cell redirecting therapies. |

| What Clinical Data Supports Tecvayli's Use? |
| :----------------------------------------------------- |
| Tecvayli's approval was based on the results of the MajesTEC-1 study, which demonstrated significant efficacy in patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy [2]. The study showed high overall response rates and durable responses, supporting its clinical utility. |

| What Are the Potential Side Effects of Tecvayli? |
| :----------------------------------------------------- |
| Common side effects associated with Tecvayli include infections, neutropenia, anemia, thrombocytopenia, diarrhea, and cytokine release syndrome (CRS) [3]. CRS is a serious adverse event that requires careful monitoring and management. |

Sources:
1. https://drugpatentwatch.com/
2. Data on file, Janssen.
3. FDA Prescribing Information for Tecvayli.